Cybin Inc. Reports First Quarter Financial Results and Recent Business Highlights
Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing Psychedelics to TherapeuticsTM, today reported unaudited financial results for its first quarter ended June 30, 2022 and recent business highlights.
- Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing Psychedelics to TherapeuticsTM, today reported unaudited financial results for its first quarter ended June 30, 2022 and recent business highlights.
- Recent Business and Pipeline Highlights:
Initiated enrollment for its first-in-human Phase 1/2a trial of CYB003 in major depressive disorder (MDD). - Based on preclinical data, CYB003 achieved less variability in plasma levels, faster onset of action, and shorter duration of effect.
- If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybins performance and operations.